Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
DUBLIN, Ireland--(BUSINESS WIRE)--Apr. 11, 2014-- Covidien plc today announced that it has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline™...
MINNEAPOLIS - April 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with...
MINNEAPOLIS - April 10, 2016 - This weekend, an article was published in the Minneapolis Star Tribune that criticized Medtronic's handling of data collected during a retrospective chart review...
MINNEAPOLIS - April 9, 2014 - Medtronic today announced CE (Conformité Européenne) Mark and European launch of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System,...
ISTANBUL - April 7, 2014 - Medtronic, Inc. today announced that one of its subsidiaries has acquired a majority of the shares of Biostar, which will assume the distribution of Medtronic products...
LONDON -- April 5, 2014 --Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated...
MINNEAPOLIS - March 31, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the final follow-up results from the CoreValve® CE Pivotal Study, which demonstrated excellent long-term durability at...
MINNEAPOLIS - March 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the European Patent Office (EPO) has invalidated, in its entirety, the Edwards Lifesciences EP2055266 Spenser patent...
MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global...
MINNEAPOLIS and WASHINGTON - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the one-year results of the Melody® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study, which...